General Biotechnology

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives

Pharmaceutical patent strategy is often discussed like a courtroom drama: file early, argue hard, win big.
But the real cost isn’t just legal fees—it’s the opportunity cost of building portfolios that look impressive on paper and fail in practice.
In a…

Cut, Keep, or Cash In: The Pharmaceutical Patent Decision Matrix That Separates Winning Portfolios from Expensive Archives Read Post »

Uncategorized

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out

The clock is ticking—so why are so many commercial market access teams waiting until after the patent clock runs out?
In pharma, timing isn’t just strategy—it’s survival.
A lot of business development (BD) in commercial market access still behaves like…

Business Development Guide for Commercial & Market Access Vendors: Sell Before the Drug Patent Clock Runs Out Read Post »

General Biotechnology

Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion

Sell the line before the patent breaks.
In pharma, timing isn’t just strategy—it’s survival. The market doesn’t wait for your sales cycle, your procurement lead times, or your customer’s internal approvals. By the time a patent cliff hits, the winner…

Sell the Line Before the Patent Breaks: A Business Development Guide for Solid Dose Equipment & Manufacturing Technology Suppliers Targeting Pre-LOE Generic Expansion Read Post »

Biotechblog
Scroll to Top